Mode
Text Size
Log in / Sign up

Systematic review links gut-lung axis in COPD and inflammatory bowel diseaseShared genes link COPD and inflammatory bowel disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Recognize that COPD and IBD share genetic and immunological mechanisms via the gut-lung axis, though evidence remains qualitative.

This systematic review explores the mechanistic overlap between chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD), focusing on the gut-lung axis. The authors synthesize evidence from genome-wide association studies (GWAS) and immunological research to identify shared susceptibility pathways.

Key findings include genetic pleiotropy underpinning a shared vulnerability to mucosal defense deficits, aberrant immune cell homing with Th17/Treg imbalance, and cross-organ trafficking of innate lymphoid cells (ILCs) that mediate distal dissemination of inflammation. Additionally, gut dysbiosis-induced depletion of short-chain fatty acids (SCFAs), acting with systemic hypoxia and the IL-23/IL-17 axis, is proposed to potentiate synergistic injury to gut-lung barriers.

The review discusses a reciprocal, bidirectional 'hypoxic loop' and its testable mechanistic predictions for barrier dysfunction, but no causal evidence is presented. Limitations are not explicitly reported, and no quantitative data or pooled effect sizes are provided.

Clinicians should recognize this as a qualitative synthesis of mechanistic hypotheses. The findings do not support specific therapeutic recommendations but may inform future research directions targeting shared inflammatory pathways in COPD and IBD.

If you have chronic obstructive pulmonary disease (COPD), you might also be at risk for inflammatory bowel disease (IBD), and vice versa. A new systematic review of genetic studies suggests that these two seemingly unrelated conditions share a common genetic vulnerability.

The review looked at genome-wide association studies (GWAS) and found that genetic pleiotropy—where the same genes influence multiple traits—underpins a shared susceptibility to defects in the body's mucosal defenses. This means that problems with the protective barriers in your lungs and gut may stem from the same genetic roots.

Beyond genetics, the review also highlights how immune cells can travel between the gut and lungs, spreading inflammation. An imbalance in certain immune cells, along with changes in gut bacteria that reduce beneficial short-chain fatty acids, may worsen damage to both organs. The authors describe a "hypoxic loop" where low oxygen levels fuel a cycle of injury.

It's important to note that this is a review of existing studies, not new research. No specific treatments were tested, and the findings are based on patterns, not proven cause-and-effect. Still, the results offer a clearer picture of why lung and gut health are so closely linked.

What this means for you:
COPD and IBD share genetic risk factors that affect immune barriers in the lungs and gut.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
The significant bidirectional comorbidity risk and extensive subclinical involvement observed between chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD) underscore the pivotal role of the “gut-lung axis” in cross-organ pathological crosstalk. Here, we comprehensively review the molecular and immunological mechanisms driving this comorbidity. Genome-wide association studies (GWAS) have substantiated genetic pleiotropy that underpins a shared susceptibility to mucosal defense deficits. The “common mucosal immune system” (CMIS), rooted in embryonic homology, constitutes the anatomical basis for this pathological interplay, wherein aberrant immune cell homing, Th17/Treg imbalance, and the cross-organ trafficking of innate lymphoid cells (ILCs) mediate the distal dissemination of inflammation. Furthermore, gut dysbiosis-induced depletion of short-chain fatty acids (SCFAs), acting in concert with systemic hypoxia and the IL-23/IL-17 axis, potentiates synergistic injury to the gut-lung barriers. We highlight the reciprocal, bidirectional causality of this “hypoxic loop” and its testable mechanistic predictions for barrier dysfunction. Furthermore, we evaluate pharmacological evidence from drug repositioning, alongside a critical examination of the “hidden axis” of clinical therapies as profound iatrogenic confounders. Elucidating these mechanisms is critical for establishing systemic diagnostic and therapeutic strategies; interventions targeting shared molecular targets and the microbiota hold promise for achieving a simultaneous treatment approach for these distinct pathologies.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.